PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia

References

• Wyatt KD, Bram RJ. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. Hum Immunol. 2019;80:400–408.
   PubMed Web of Science ®Google Scholar
• Jasinski S, De Los Reyes FA, Yametti GC, et al. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22:485–499.
   PubMed Web of Science ®Google Scholar
• Poulard C, Kim HN, Fang M, et al. Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2019;116:3052–3061.
   PubMed Web of Science ®Google Scholar
• Bhadri VA, Trahair TN, Lock RB. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health. 2012;48:634–640.
   PubMed Web of Science ®Google Scholar
• Toscan CE, Jing D, Mayoh C, et al. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression. Br J Cancer. 2020;122:1769–1781.
   PubMed Web of Science ®Google Scholar
• Bacchetti T, Salvolini E, Pompei V, et al. Paraoxonase-2: A potential biomarker for skin cancer aggressiveness. Eur J Clin Invest. 2020;51(5):e13452.
   Web of Science ®Google Scholar
• Nagarajan A, Dogra SK, Sun L, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol Cell. 2017;67:685–701. e686.
   PubMed Web of Science ®Google Scholar
• Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951–2959.
   PubMed Web of Science ®Google Scholar
• Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115:1394–1405.
   PubMed Web of Science ®Google Scholar
• Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20:1400–1407.
   PubMed Web of Science ®Google Scholar
• Pise-Masison CA, Radonovich M, Mahieux R, et al. Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes. Cancer Res. 2002;62:3562–3571.
   PubMed Web of Science ®Google Scholar
• Pan L, Hong C, Chan LN, et al. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proc Natl Acad Sci U S A. 2021;118(7):e2016553118.
   Web of Science ®Google Scholar
• Kruth KA, Fang M, Shelton DN, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. 2017;129:3000–3008.
   PubMed Web of Science ®Google Scholar
• Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331–342.
   PubMed Web of Science ®Google Scholar
• Accordi B, Galla L, Milani G, et al. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia. 2013;27:1019–1027.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu P, Ma D, et al. Glucocorticoid resistance induced by ANXA5 overexpression in B-cell acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2021;38(1):36–48.
   Web of Science ®Google Scholar
• Consolaro F, Ghaem-Maghami S, Bortolozzi R, et al. FOXO3a and posttranslational modifications mediate glucocorticoid sensitivity in B-ALL. Mol Cancer Res: MCR. 2015;13:1578–1590.
   PubMed Web of Science ®Google Scholar
• Chougule RA, Shah K, Moharram SA, et al. Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. NPJ Genom Med. 2019;4:7.
   PubMed Web of Science ®Google Scholar
• Li J, Chen R, Yao QY, et al. Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model. Acta Pharmacol Sin. 2018;39:472–481.
   PubMed Web of Science ®Google Scholar
• Bhadri VA, Cowley MJ, Kaplan W, et al. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia. BMC Genomics. 2011;12:565.
   PubMed Web of Science ®Google Scholar
• Richartz N, Duthil E, Ford A, et al. Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. Blood Adv. 2019;3:3181–3190.
   PubMed Web of Science ®Google Scholar
• Tissing WJ, Meijerink JP, Brinkhof B, et al. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood. 2006;108:1045–1049.
   PubMed Web of Science ®Google Scholar
• Riml S, Schmidt S, Ausserlechner MJ, et al. Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in jurkat acute lymphoblastic leukemia cells. Cell Death Differ. 2004;11(Suppl 1):S65–S72.
   PubMedGoogle Scholar
• Ramdas J, Liu W, Harmon JM. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 1999;59:1378–1385.
   PubMed Web of Science ®Google Scholar
• Marke R, Havinga J, Cloos J, et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2016;30:1599–1603.
   PubMed Web of Science ®Google Scholar
• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.
   PubMed Web of Science ®Google Scholar
• Poulard C, Baulu E, Lee BH, et al. Increasing G9a automethylation sensitizes B acute lymphoblastic leukemia cells to glucocorticoid-induced death. Cell Death Dis. 2018;9:1038.
   PubMed Web of Science ®Google Scholar
• Bortolozzi R, Mattiuzzo E, Trentin L, et al. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All). Biochem Pharmacol. 2018;153:230–241.
   PubMed Web of Science ®Google Scholar
• Evangelisti C, Cappellini A, Oliveira M, et al. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. J Cell Physiol. 2018;233:1796–1811.
   PubMed Web of Science ®Google Scholar
• Bacchetti T, Ferretti G, Sahebkar A. The role of paraoxonase in cancer. Semin Cancer Biol. 2019;56:72–86.
   PubMed Web of Science ®Google Scholar
• Campagna R, Bacchetti T, Salvolini E, et al. Paraoxonase-2 silencing enhances sensitivity of A375 melanoma cells to treatment with cisplatin. Antioxidants. 2020;9(12):1238.
   Web of Science ®Google Scholar
• Chan LN, Chen Z, Braas D, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479–483.
   PubMed Web of Science ®Google Scholar
• Liu T, Kishton RJ, Macintyre AN, et al. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis. 2014;5:e1470.
   PubMed Web of Science ®Google Scholar